BACKGROUND: Co-morbidity of schizophrenia (SZ) and metabolic problems such as diabetes mellitus (DM) has been suggested by many studies. Nonetheless, it is still debated whether DM affects cognitive dysfunction associated with SZ and how much treatment for DM is beneficial for cognitive functions in SZ. We addressed these questions by re-assessing the cognitive dataset from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study. METHODS: We identified 1289 SZ patients in which scores for several cognitive domains of verbal memory, vigilance, processing speed, reasoning, and working memory together with the composite score and metabolic characteristics (body mass index, dyslipidemia, hypertension, and DM) were available at baseline of the trial. We performed multiple linear regression analyses to assess the impact of DM on cognitive performance of SZ patients, controlling for a number of other confounding factors including obesity, hypertension, and dyslipidemia. We also conducted analyses of covariance to compare cognitive performance among SZ patients without DM and diabetic SZ sub-groups based on anti-diabetic drugs they were receiving at baseline of the trial. RESULTS: Co-morbid DM with SZ predicted worse overall cognitive performance and lower scores for three cognitive domains (vigilance, processing speed, and reasoning), but none of the other metabolic factors (i.e., obesity, hypertension and dyslipidemia) correlated with cognitive function in SZ. Furthermore, SZ patients with untreated DM showed poorer overall cognitive performance and a significantly lower score in the domain of vigilance compared with SZ patients without DM. CONCLUSION: Our data suggest that DM negatively affects the overall cognitive function of SZ patients.
BACKGROUND: Co-morbidity of schizophrenia (SZ) and metabolic problems such as diabetes mellitus (DM) has been suggested by many studies. Nonetheless, it is still debated whether DM affects cognitive dysfunction associated with SZ and how much treatment for DM is beneficial for cognitive functions in SZ. We addressed these questions by re-assessing the cognitive dataset from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study. METHODS: We identified 1289 SZ patients in which scores for several cognitive domains of verbal memory, vigilance, processing speed, reasoning, and working memory together with the composite score and metabolic characteristics (body mass index, dyslipidemia, hypertension, and DM) were available at baseline of the trial. We performed multiple linear regression analyses to assess the impact of DM on cognitive performance of SZ patients, controlling for a number of other confounding factors including obesity, hypertension, and dyslipidemia. We also conducted analyses of covariance to compare cognitive performance among SZ patients without DM and diabetic SZ sub-groups based on anti-diabetic drugs they were receiving at baseline of the trial. RESULTS: Co-morbid DM with SZ predicted worse overall cognitive performance and lower scores for three cognitive domains (vigilance, processing speed, and reasoning), but none of the other metabolic factors (i.e., obesity, hypertension and dyslipidemia) correlated with cognitive function in SZ. Furthermore, SZ patients with untreated DM showed poorer overall cognitive performance and a significantly lower score in the domain of vigilance compared with SZ patients without DM. CONCLUSION: Our data suggest that DM negatively affects the overall cognitive function of SZ patients.
Authors: Bruce L Lambert; Francesca E Cunningham; Donald R Miller; Gregory W Dalack; Kwan Hur Journal: Am J Epidemiol Date: 2006-08-30 Impact factor: 4.897
Authors: David C Henderson; Christina P Borba; Tara B Daley; Ryan Boxill; Dana D Nguyen; Melissa A Culhane; Pearl Louie; Corinne Cather; A Eden Evins; Oliver Freudenreich; Sarah M Taber; Donald C Goff Journal: Ann Clin Psychiatry Date: 2006 Apr-Jun Impact factor: 1.567
Authors: Hannu Juvonen; Antti Reunanen; Jari Haukka; Maria Muhonen; Jaana Suvisaari; Ritva Arajärvi; Timo Partonen; Jouko Lönnqvist Journal: Arch Gen Psychiatry Date: 2007-08
Authors: Richard S E Keefe; Robert M Bilder; Philip D Harvey; Sonia M Davis; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; Del D Miller; Jose M Canive; Lawrence W Adler; Theo C Manschreck; Marvin Swartz; Robert Rosenheck; Diana O Perkins; Trina M Walker; T Scott Stroup; Joseph P McEvoy; Jeffrey A Lieberman Journal: Neuropsychopharmacology Date: 2006-04-19 Impact factor: 7.853
Authors: Jaana Suvisaari; Jonna Perälä; Samuli I Saarni; Tommi Härkänen; Sami Pirkola; Matti Joukamaa; Seppo Koskinen; Jouko Lönnqvist; Antti Reunanen Journal: Eur Arch Psychiatry Clin Neurosci Date: 2008-04 Impact factor: 5.270
Authors: Dwight Dickinson; James M Gold; Faith B Dickerson; Deborah Medoff; Lisa B Dixon Journal: Psychosomatics Date: 2008 Mar-Apr Impact factor: 2.386
Authors: Fernando Caravaggio; Margaret Hahn; Shinichiro Nakajima; Philip Gerretsen; Gary Remington; Ariel Graff-Guerrero Journal: Med Hypotheses Date: 2015-06-24 Impact factor: 1.538
Authors: Colin A Depp; Martin Strassnig; Brent T Mausbach; Christopher R Bowie; Paula Wolyniec; Mary H Thornquist; James R Luke; John A McGrath; Ann E Pulver; Thomas L Patterson; Philip D Harvey Journal: Bipolar Disord Date: 2014-04-12 Impact factor: 6.744
Authors: Eduardo De la Cruz-Cano; Carlos Alfonso Tovilla-Zarate; Emilio Reyes-Ramos; Thelma Beatriz Gonzalez-Castro; Isela Juarez-Castro; Maria Lilia López-Narváez; Ana Fresan Journal: F1000Res Date: 2015-01-09
Authors: Katarzyna Adamowicz; Aleksandra Mazur; Monika Mak; Jerzy Samochowiec; Jolanta Kucharska-Mazur Journal: Front Psychiatry Date: 2020-04-30 Impact factor: 4.157
Authors: Priyanthi B Gjerde; Carmen E Simonsen; Trine V Lagerberg; Nils E Steen; Torill Ueland; Ole A Andreassen; Vidar M Steen; Ingrid Melle Journal: Eur Arch Psychiatry Clin Neurosci Date: 2019-04-27 Impact factor: 5.270